A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

• Status: Terminated
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Tamoxifen; Vorinostat

Criteria

Inclusion Criteria:

• Stage I-III invasive breast cancer

• Awaiting surgery or neoadjuvant treatment

• ECOG performance status 0, 1 or 2

• Adequate organ function

• Prior use of hormone contraception or replacement therapy must have been discontinued at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo an additional biopsy for the study)

Exclusion Criteria:

• Prior or current treatment of any kind for the current breast cancer

• Current use of any other investigational drugs

• Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or psychiatric illness